摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-2H-isoquinolin-1-one | 680223-48-7

中文名称
——
中文别名
——
英文名称
(R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-2H-isoquinolin-1-one
英文别名
3-[2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-2H-isoquinolin-1-one
(R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-2H-isoquinolin-1-one化学式
CAS
680223-48-7
化学式
C16H20N2O2
mdl
——
分子量
272.347
InChiKey
OKVBEBCBQZYBLN-CQSZACIVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    52.6
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    N,N-二乙基-2,3-二甲基苯甲酰胺3-[(2R)-2-(羟基甲基)-1-吡咯烷基]丙腈 以(R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-2H-isoquinolin-1-one (408.4 mg) was obtained的产率得到(R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-2H-isoquinolin-1-one
    参考文献:
    名称:
    Isoquinoline compound and pharmaceutical use thereof
    摘要:
    本发明涉及一种由以下式(I)表示的异喹啉化合物,其光学活性形式,其药学上可接受的盐,其水加合物,其水合物和其溶剂合物,以及用于预防和/或治疗由多聚(ADP-核糖)聚合酶的高反应性引起的疾病的药物,其中包含该化合物,以及含有该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外,该化合物可用作预防和/或治疗脑梗死的药物,特别是作为预防和/或治疗急性脑梗死的药物。此外,该化合物可用作预防和/或治疗与脑梗死相关的神经症状的预防和/或治疗剂,特别是急性脑梗死。其中符号与说明中定义的相同。
    公开号:
    US20040248931A1
点击查看最新优质反应信息

文献信息

  • ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF
    申请人:Fujio Masakazu
    公开号:US20070161620A1
    公开(公告)日:2007-07-12
    The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
    本发明涉及以下式(I)所表示的异喹啉化合物,其手性活性形式,其药学上可接受的盐,其水加合物,其水合物和其溶剂化物,以及包含该化合物的用于预防和/或治疗由多聚(ADP-核糖)聚合酶过度反应所致疾病的药剂和包含该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外,该化合物可用作预防和/或治疗脑梗死的药剂,特别是作为预防和/或治疗急性脑梗死的药剂。此外,该化合物可用作改善与脑梗死相关的神经症状的预防性和/或治疗性药剂,特别是急性脑梗死。其中符号与描述中定义的相同。
  • ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1557414A1
    公开(公告)日:2005-07-27
    The present invention relates to an isoquinoline compound represented by the following formula (1), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction.
    本发明涉及下式(1)代表的异喹啉化合物、其光学活性形式、其药学上可接受的盐、其水加合物、其水合物和其溶解物,以及含有该化合物的预防和/或治疗由聚(ADP-核糖)聚合酶高反应性引起的疾病的制剂和含有该化合物的聚(ADP-核糖)聚合酶抑制剂。此外,该化合物还可作为预防和/或治疗脑梗塞的药物,特别是作为预防和/或治疗急性脑梗塞的药物。此外,该化合物还可作为预防和/或治疗剂,改善与脑梗塞,尤其是急性脑梗塞相关的神经症状。
  • US7220759B2
    申请人:——
    公开号:US7220759B2
    公开(公告)日:2007-05-22
  • US7459465B2
    申请人:——
    公开号:US7459465B2
    公开(公告)日:2008-12-02
  • US7812178B2
    申请人:——
    公开号:US7812178B2
    公开(公告)日:2010-10-12
查看更多